Client Alerts & Insights
Eleventh Circuit Upholds Dismissal of Qui Tam FCA Suit for Failure to Meet Rule 9(b) Specificity
August 21, 2025
Authored By:
Overview In a qui tam action filed under the False Claims Act, the relator, Barbara Senters, appealed the district court’s dismissal of her fourth amended complaint (FAC), which alleged that Quest Diagnostics submitted false claims for medically unnecessary lab tests by using confusing “custom panels.” See United States ex rel Senters v. Quest Diagnostics, No. 24-12998 (11th Cir. 2025). The Eleventh Circuit affirmed the dismissal, finding the FAC did not satisfy the heightened factual pleading standards required by Federal Rule of Civil Procedure 9(b).
Rule 9(b) Requires Particularity: The “Who, What, Where, When, and How” of a False Claim
- A relator must plead with particularity the submission of a false claim—not just the existence of a fraudulent scheme. General allegations or inferences are insufficient.
- The complaint must identify a representative false claim and detail why it was false (e.g., medically unnecessary, knowingly submitted) and who submitted it, when, and how. The Court reiterated that even a credible fraudulent scheme must be connected to an actual false claim submitted to the government to support liability under 31 U.S.C. § 3729(a)(1)(A) or (B).
Access Is Not Enough
Although Ms. Senters, a former compliance officer, had knowledge of billing practices and access to records, the court held that such access does not substitute for particularized factual allegations about the false claims.
Practical Implications for Clients and Counsel
- When advising clients, especially in healthcare or billing sectors:
- Ensure that any FCA-related complaint, especially by whistleblowers, includes precise details:
- Identify specific claims (dates, amounts, procedure codes).
- Demonstrate a factual basis for why the services were not medically necessary.
- Trace who submitted the claim and how the falsity was known.
- Internal audit and compliance teams must document thoroughly:
- If potential billing issues arise, maintain detailed records, email communications, and documentation that support the unreasonableness or inaccuracy of a claim.
- Evidence showing that a provider actually knew (or should have known) a claim was false.
- Relators cannot rely solely on internal access or general knowledge alone; this decision suggests courts view such knowledge skeptically without corroborating factual specifics.
- In cases with potential FCA exposure, consider how much detail is available before proceeding with litigation—or before choosing to defend a case if the complaint survives.
Latest News
FTC Enforcement Trends in 2026: What Businesses, Advertisers Should Be Watching Now
Regulators continue to signal a return to core consumer‑friendly principles through new rulemaking initiatives, and recent enforcement activity, warning letters, and public commentary offer a practical preview of where scrutiny is likely to concentrate in 2026…
IEEPA Tariffs – Top Five Q&A for Supply Chains after U.S. Supreme Court Decision
The U.S. Supreme Court issued its highly anticipated decision regarding tariffs Friday. The Court held that the International Emergency Economic Powers Act (“IEEPA”) does not authorize the President to impose tariffs according to the 6-3 decision…
Watch Your T&Cs! When Done Right, Terms and Conditions are Both Viable—And Valuable
The era of the paper/hard copy bill of lading and/or rate confirmation is fading fast. Hard copies and paper do live on in various shipment schematics; however, increasingly, and at a very rapid rate, transactions between shippers, carriers, brokers and forwarders are conducted by, and memorialized in, electronic form via email, interactive website access and response, and—more and more—AI mechanisms.
The Long Tail of the Opioid Crisis: How AGs Continue to Pursue Manufacturers, Distributors, Pharmacies
The opioid crisis has been a perennial priority for state attorneys general, and was the marquis priority for the National Association of Attorneys General (NAAG) in both 2023 (under OH AG Dave Yost) and 2025 (under NH AG John Formella). Recently, Texas Attorney General Ken Paxton announced the conclusion of a multistate effort to secure the bankruptcy reorganization plan for Purdue Pharma (Purdue).